메뉴 건너뛰기




Volumn 24, Issue 1, 2014, Pages 19-41

A regulatory perspective on essential considerations in design and analysis of subgroups when correctly classified

Author keywords

Biomarker; Formation of subgroup; Interaction to overall effects ratio; Predictive of treatment effect; Subgroup specific treatment effect hypothesis

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; CLINICAL RESEARCH; DATA ANALYSIS; EFFECT SIZE; HOMOGENATE; HUMAN; HYPOTHESIS; INTENTION TO TREAT ANALYSIS; PATIENT CODING; PRIORITY JOURNAL; SAMPLE SIZE;

EID: 84888130933     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2013.856022     Document Type: Article
Times cited : (22)

References (42)
  • 2
    • 84891812279 scopus 로고    scopus 로고
    • Brilinta label. Available at
    • Brilinta label. (2013). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2013/022433s006lbl.pdf
    • (2013)
  • 3
    • 1842453957 scopus 로고    scopus 로고
    • Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; Power and sample size for the interaction test
    • Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., Peters, T. J. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 57:229-236.
    • (2004) Journal of Clinical Epidemiology , vol.57 , pp. 229-236
    • Brookes, S.T.1    Whitely, E.2    Egger, M.3    Smith, G.D.4    Mulheran, P.A.5    Peters, T.J.6
  • 4
  • 6
    • 84891770167 scopus 로고    scopus 로고
    • Diovan label. Available at
    • Diovan label. (2002). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2002/20665s16lbl.pdf
    • (2001)
  • 7
    • 84891797487 scopus 로고    scopus 로고
    • Erbitux label. Available at
    • Erbitux label. (2012). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2012/125084s225lbl.pdf
    • (2012)
  • 8
    • 84891799670 scopus 로고    scopus 로고
    • Food and Drug Administration. Available at
    • Food and Drug Administration. (2013). Health Human Services, Code of Federal Regulation, 21CFR314.126. Available at: http://www.accessdata.fda.gov/ scripts/ cdrh/ cfdocs/cfcfr/CFRSearch.cfm?fr=314.126
    • (2013) Health Human Services, Code of Federal Regulation, 21CFR314.126
  • 11
    • 27744537954 scopus 로고    scopus 로고
    • Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients
    • Freidlin, B., Simon, R. (2005). Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 11:7872-7878.
    • (2005) Clinical Cancer Research , vol.11 , pp. 7872-7878
    • Freidlin, B.1    Simon, R.2
  • 13
    • 46449103363 scopus 로고    scopus 로고
    • PREDICT-1: The first powered prospective trial of pharmacogenetic screening to reduce drug adverse events
    • CNA106030 Study team
    • Hughes, S., Hughes, A., Brothers, C., Spreen, W., Thorborn, D., CNA106030 Study team. (2008). PREDICT-1: The first powered prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharmaceutical Statistics 7:121-129.
    • (2008) Pharmaceutical Statistics , vol.7 , pp. 121-129
    • Hughes, S.1    Hughes, A.2    Brothers, C.3    Spreen, W.4    Thorborn, D.5
  • 14
    • 77957340034 scopus 로고    scopus 로고
    • Consideration of regional difference in design and analysis of multi-regional trials
    • Hung, H. M. J., Wang, S. J., O'Neill, R. (2010). Consideration of regional difference in design and analysis of multi-regional trials. Pharmaceutical Statistics 9:173-178.
    • (2010) Pharmaceutical Statistics , vol.9 , pp. 173-178
    • Hung, H.M.J.1    Wang, S.J.2    O'neill, R.3
  • 18
    • 0034831901 scopus 로고    scopus 로고
    • Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure
    • Highlights of the scientific sessions of the American College of Cardiology, 2001
    • Louis, A., Cleland, J. G. F., Crabbe, S., Ford, S., Thackray, S., Houghton, T., Clark, A. (2001). Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001. European Journal of Heart Failure 3:381-387.
    • (2001) European Journal of Heart Failure , vol.3 , pp. 381-387
    • Louis, A.1    Cleland, J.G.F.2    Crabbe, S.3    Ford, S.4    Thackray, S.5    Houghton, T.6    Clark, A.7
  • 20
    • 61349150491 scopus 로고    scopus 로고
    • Optimizing trial design: Sequential, adaptive, and enrichment strategies
    • Mehta, C., Gao, P., Bhatt, D. L., Harrington, R. A., Skerjanec, S., Ware, J. H. (2009). Optimizing trial design: Sequential, adaptive, and enrichment strategies. Circulation 119:597-605.
    • (2009) Circulation , vol.119 , pp. 597-605
    • Mehta, C.1    Gao, P.2    Bhatt, D.L.3    Harrington, R.A.4    Skerjanec, S.5    Ware, J.H.6
  • 21
    • 84873817347 scopus 로고    scopus 로고
    • A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials
    • doi:10.1177/0092861512454116
    • Millen, B. A., Dmitrienko, A., Ruberg, S., Shen, L. (2012). A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials. Drug Information Journal. doi:10.1177/0092861512454116.
    • (2012) Drug Information Journal
    • Millen, B.A.1    Dmitrienko, A.2    Ruberg, S.3    Shen, L.4
  • 22
    • 58149343878 scopus 로고    scopus 로고
    • K-Ras mutations are changing practice in advanced colorectal cancer
    • McNeil, C. (2008). K-Ras mutations are changing practice in advanced colorectal cancer. Journal of National Cancer Institute 100(23):1667-1669.
    • (2008) Journal of National Cancer Institute , vol.100 , Issue.23 , pp. 1667-1669
    • McNeil, C.1
  • 23
    • 0001474703 scopus 로고
    • NIH guidelines on the inclusion of women and minorities as subjects in clinical research
    • National Institutes of Health
    • National Institutes of Health. (1994). NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register 59:14508-14513.
    • (1994) Federal Register , vol.59 , pp. 14508-14513
  • 25
    • 84891793993 scopus 로고    scopus 로고
    • President signs FDA user fee bill as industry begins watching for implementation issues. Available at
    • President signs FDA user fee bill as industry begins watching for implementation issues. (2012). Sidley.com. Available at: http://www.sidley.com/ President-Signs-FDA-User- Fee-Bill-as-Industry-Begins-Watching-for- Implementation-Issues-07-09-2012
    • (2012) Sidley.com
  • 27
    • 84864820652 scopus 로고    scopus 로고
    • Testing a prespecified subgroup and the intent-to-treat population
    • Rothman, M. D., Zhang, J. J., Lu, L., Fleming, T. R. (2012). Testing a prespecified subgroup and the intent-to-treat population. Drug Information Journal 46:175-179.
    • (2012) Drug Information Journal , vol.46 , pp. 175-179
    • Rothman, M.D.1    Zhang, J.J.2    Lu, L.3    Fleming, T.R.4
  • 28
    • 11844302840 scopus 로고    scopus 로고
    • Subgroup analysis in randomized controlled trials: Importance, indications, and interpretation
    • Rothwell, P. (2005). Subgroup analysis in randomized controlled trials: Importance, indications, and interpretation. Lancet 365:176-186.
    • (2005) Lancet , vol.365 , pp. 176-186
    • Rothwell, P.1
  • 29
    • 33646047815 scopus 로고    scopus 로고
    • Use of genomic signatures in therapeutics development in oncology and other diseases. Advance online publication, January 17, 2006
    • Simon, R., Wang, S. J. (2006). Use of genomic signatures in therapeutics development in oncology and other diseases. Advance online publication, January 17, 2006. Pharmacogenomics Journal 6:166-173.
    • (2006) Pharmacogenomics Journal , vol.6 , pp. 166-173
    • Simon, R.1    Wang, S.J.2
  • 30
    • 0021137170 scopus 로고
    • The design of case-control studies: The influence of confounding and interaction effects
    • Smith, P. G., Day, N. E. (1984). The design of case-control studies: The influence of confounding and interaction effects. International Journal of Epidemiology 13:356-365.
    • (1984) International Journal of Epidemiology , vol.13 , pp. 356-365
    • Smith, P.G.1    Day, N.E.2
  • 32
    • 18744406319 scopus 로고    scopus 로고
    • Multiplicity in randomized controlled trials II: Subgroup and interim analyses
    • Schultz, K. F., Grimes, D. A. (2005). Multiplicity in randomized controlled trials II: Subgroup and interim analyses. Lancet 365:1657-1661.
    • (2005) Lancet , vol.365 , pp. 1657-1661
    • Schultz, K.F.1    Grimes, D.A.2
  • 33
    • 84891775845 scopus 로고    scopus 로고
    • Tarceva label. Available at
    • Tarceva label. (2013). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2013/021743s018lbl.pdf
    • (2013)
  • 34
    • 84891797795 scopus 로고    scopus 로고
    • Xigris label. Available at
    • Xigris label. (2007). Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/ 2007/125029s080LBL.pdf
    • (2007)
  • 35
    • 37349069551 scopus 로고    scopus 로고
    • Biomarker as a classifier in pharmacogenomics clinical trials: A tribute to 30th anniversary of PSI
    • Wang, S. J. (2007). Biomarker as a classifier in pharmacogenomics clinical trials: A tribute to 30th anniversary of PSI. Pharmaceutical Statistics 6:283-296.
    • (2007) Pharmaceutical Statistics , vol.6 , pp. 283-296
    • Wang . S, J.1
  • 36
    • 33645061021 scopus 로고    scopus 로고
    • Retrospective validation of genomic biomarkers - What are the questions, challenges and strategies for developing useful relationships to clinical outcomes - Workshop summary
    • Wang, S. J., Cohen, N., Katz, D. A., Ruano, G., Shaw, P., Spear, B. (2006). Retrospective validation of genomic biomarkers - What are the questions, challenges and strategies for developing useful relationships to clinical outcomes - Workshop summary. Pharmacogenomics Journal 6:82-88.
    • (2006) Pharmacogenomics Journal , vol.6 , pp. 82-88
    • Wang, S.J.1    Cohen, N.2    Katz, D.A.3    Ruano, G.4    Shaw, P.5    Spear, B.6
  • 37
    • 84866271129 scopus 로고    scopus 로고
    • Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials
    • Wang, S. J., Hung, H. M. J. (2012). Ethnic sensitive or molecular sensitive beyond all regions being equal in multiregional clinical trials. Journal of Biopharmaceutical Statistics 22:879-893.
    • (2012) Journal of Biopharmaceutical Statistics , vol.22 , pp. 879-893
    • Wang, S.J.1    Hung, H.M.J.2
  • 38
    • 66349125688 scopus 로고    scopus 로고
    • Adaptive patient enrichment designs in therapeutic trials
    • Wang, S. J., Hung, H. M. J., O'Neill, R. T. (2009). Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 51(2):358-374.
    • (2009) Biometrical Journal , vol.51 , Issue.2 , pp. 358-374
    • Wang, S.J.1    Hung, H.M.J.2    O'neill, R.T.3
  • 39
    • 34648840242 scopus 로고    scopus 로고
    • Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
    • Wang, S. J., O'Neill, R. T., Hung, H. M. J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227-244.
    • (2007) Pharmaceutical Statistics , vol.6 , pp. 227-244
    • Wang, S.J.1    O'neill, R.T.2    Hung, H.M.J.3
  • 40
    • 78649960550 scopus 로고    scopus 로고
    • Some statistical considerations in evaluating pharmacogenomics confirmatory clinical trials
    • Wang, S. J., O'Neill, R. T., Hung, H. M. J. (2010). Some statistical considerations in evaluating pharmacogenomics confirmatory clinical trials. Clinical Trials 7:525-536.
    • (2010) Clinical Trials , vol.7 , pp. 525-536
    • Wang, S.J.1    O'neill, R.T.2    Hung, H.M.J.3
  • 42
    • 0025737883 scopus 로고
    • Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Special communication
    • Yusuf, S., Wittes, J., Probstfield, J., Tyroler, H. A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Special communication. Journal of the American Medical Association 266(1):93-98.
    • (1991) Journal of the American Medical Association , vol.266 , Issue.1 , pp. 93-98
    • Yusuf, S.1    Wittes, J.2    Probstfield, J.3    Tyroler, H.A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.